Literature DB >> 9679948

Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.

K T Wilson1, S Fu, K S Ramanujam, S J Meltzer.   

Abstract

Barrett's esophagus is a premalignant condition arising in response to chronic reflux esophagitis. Inducible nitric oxide synthase (iNOS; NOS-2) and cyclooxygenase-2 (COX-2) are mediators of inflammation and regulators of epithelial cell growth. Expression levels of iNOS and COX-2 are high in colorectal adenomas and carcinomas, and COX-2 expression is elevated in gastric cancers. To determine the involvement of iNOS and COX-2 in Barrett's-associated neoplasia, we measured expression of these genes in metaplastic Barrett's and esophageal adenocarcinomas. We detected elevated iNOS and COX-2 mRNA levels in Barrett's mucosa compared with paired gastric control tissues in 16 of 21 (76%) and 17 of 21 (80%) patients, respectively (P < 0.001 for both genes). In esophageal adenocarcinomas, iNOS and COX-2 mRNA levels were increased in four of five and five of five cases, respectively. Furthermore, in 10 of 10 Barrett's patients, immunohistochemical staining for iNOS and COX-2 expression was strongly positive and higher than in matched gastric controls. Increased COX-2 expression was confirmed by Western blotting. These findings support the hypothesis that iNOS and COX-2 are involved early and often in Barrett's-associated neoplastic progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679948

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  120 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 2.  Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

Authors:  J A Jankowski; N A Wright; S J Meltzer; G Triadafilopoulos; K Geboes; A G Casson; D Kerr; L S Young
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

3.  Expression of inducible nitric oxide synthase in human gastric cancer.

Authors:  Yu Jun; Guo Fei; Matthias P A Ebert; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

4.  Involvement of p38 MAPK-dependent activator protein (AP-1) activation in modulation of gastric mucosal inflammatory responses to Helicobacter pylori by ghrelin.

Authors:  B L Slomiany; A Slomiany
Journal:  Inflammopharmacology       Date:  2012-06-06       Impact factor: 4.473

Review 5.  Barrett's esophagus.

Authors:  Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

Review 6.  Barrett's esophagus: best of Digestive Disease Week 2003.

Authors:  Michael Jean; Kulwinder Dua
Journal:  Curr Gastroenterol Rep       Date:  2004-06

Review 7.  Review: Experimental models for Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Katherine S Garman; Roy C Orlando; Xiaoxin Chen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-15       Impact factor: 4.052

Review 8.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

9.  Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.

Authors:  Aaron P Thrift; Lesley A Anderson; Liam J Murray; Michael B Cook; Nicholas J Shaheen; Joel H Rubenstein; Hashem B El-Serag; Thomas L Vaughan; Jennifer L Schneider; David C Whiteman; Douglas A Corley
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

10.  Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett's metaplasia induced by duodenal contents reflux.

Authors:  T J Jang; S K Min; J D Bae; K H Jung; J I Lee; J R Kim; W S Ahn
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.